S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

$417.32
-1.14 (-0.27%)
(As of 03/27/2024 ET)
Today's Range
$412.65
$420.42
50-Day Range
$407.69
$446.08
52-Week Range
$309.43
$448.40
Volume
905,435 shs
Average Volume
1.04 million shs
Market Capitalization
$107.80 billion
P/E Ratio
30.04
Dividend Yield
N/A
Price Target
$417.27

Vertex Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.41 Rating Score
Upside/​Downside
0.0% Downside
$417.27 Price Target
Short Interest
Healthy
1.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.81mentions of Vertex Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$7.99 M Sold Last Quarter
Proj. Earnings Growth
8.96%
From $14.95 to $16.29 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

160th out of 939 stocks

Pharmaceutical Preparations Industry

65th out of 422 stocks

VRTX stock logo

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company headquartered in Boston, Massachusetts, was founded in 1989 by Joshua Boger and Kevin J. Kinsella with a vision to revolutionize disease treatments through rational drug design. Their mission is to "transform the way serious diseases are treated," and they have made significant strides in achieving this goal. The company specializes in researching, developing, and commercializing innovative therapies for various medical conditions, primarily focusing on cystic fibrosis. Using cutting-edge science and technology, Vertex has become a leading player in the biotech industry, particularly in the field of precision medicine.

Vertex has overcome challenges and achieved milestones, chronicled in Barry Werth's book "The Billion-Dollar Molecule." Over the years, the company's research and development efforts have primarily targeted viral infections, inflammatory and autoimmune disorders, cancer, and other specialty diseases. Vertex's flagship products are dedicated to treating cystic fibrosis, a genetic condition affecting the respiratory and digestive systems. Notable among these are Kalydeco, the first FDA-approved drug addressing the underlying cause of cystic fibrosis for specific gene mutations, Orkambi, a combination drug for patients with the most common cystic fibrosis mutation (F508del), Symdeko, a dual combination treatment for certain gene mutations and Trikafta, a groundbreaking triple-combination therapy for cystic fibrosis.

The company's target market consists of patients suffering from serious diseases, especially those with cystic fibrosis and other genetic disorders. Vertex's therapies are designed to cater to specific gene mutations, offering personalized and precision medicine approaches. Key customers include patients with cystic fibrosis and their families, healthcare providers specializing in genetic diseases and health systems, and insurers providing access to these life-changing therapies. Vertex Pharmaceuticals has achieved significant financial growth in recent years, reflecting its successful drug development efforts. Impressive revenue metrics and robust earnings metrics indicate the company's ability to translate its research into profitable treatments efficiently. The company's strong profit margin metrics also showcase its effective financial management.

The positive financial performance has driven the company's stock price upwards, reflecting investor confidence in Vertex's ability to deliver innovative therapies and capitalize on unmet medical needs. The company's strong financials, expanding product pipeline, and contributions to cystic fibrosis treatment have justified its favorable valuation compared to industry peers. Vertex Pharmaceuticals' successful development and commercialization of Trikafta have been key drivers behind the company's positive valuation and investor sentiment. The drug's significant impact on patients and its potential for continued growth have attracted investors seeking exposure to the dynamic biopharmaceutical sector.

As Vertex explores gene-editing therapies in collaboration with CRISPR Therapeutics and Arbor Biotechnologies, investors view the company as a strategic player in addressing significant unmet medical needs. The company's commitment to research and development further solidifies investor confidence in its long-term prospects.

Vertex Pharmaceuticals has demonstrated resilient stock performance. Investors recognize the company's value as a pioneer in the biotech industry, with a focus on precision medicine and transformative therapies. The company's dedication to research and its successful commercialization of existing drugs underscores its strategic positioning in the market.

As Vertex continues to expand its product pipeline and explore new treatment avenues, investors remain optimistic about the company's growth potential. The company's innovative research collaborations, particularly in gene-editing therapies, are expected to drive further positive investor sentiment. In the broader industry, Vertex Pharmaceuticals is well-positioned relative to its peers. Its specialization in precision medicine and groundbreaking therapies for genetic diseases sets it apart, giving the company a competitive advantage. Vertex's successful track record and commitment to addressing unmet medical needs further reinforce its strong position in the market.

While Vertex Pharmaceuticals has achieved significant milestones, the company faces certain risks and challenges. Regulatory hurdles, competitive pressures, and the need for continued investment in research and development are potential factors that may impact its future growth. However, the company's risk management strategies and prudent financial management are designed to mitigate potential risks and position Vertex for continued success. As the company continues to innovate and expand its product portfolio, it is expected to maintain its strong position in the biopharmaceutical industry.

VRTX Stock Price History

VRTX Stock News Headlines

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval (VRTX)
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
3 Biopharma Stocks Predicted to Soar in Q2 2024
VRTX Mar 2024 335.000 put
Q4 2023 MaxCyte Inc Earnings Call
The Top 3 Biotech Stocks to Buy in March 2024
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
5,400
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$417.27
High Stock Price Target
$540.00
Low Stock Price Target
$325.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
22 Analysts

Profitability

Net Income
$3.62 billion
Pretax Margin
44.38%

Debt

Sales & Book Value

Annual Sales
$9.87 billion
Cash Flow
$14.70 per share
Book Value
$68.22 per share

Miscellaneous

Free Float
257,533,000
Market Cap
$107.80 billion
Optionable
Optionable
Beta
0.35

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Vertex Pharmaceuticals was last updated on Sunday, March 24, 2024 at 3:26 PM.

Pros

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • Vertex Pharmaceuticals has a strong market capitalization of $106.38 billion, indicating stability and potential for growth.
  • The company's stock price has shown resilience, with a 12-month high of $448.40, suggesting positive investor sentiment.
  • Vertex Pharmaceuticals has a low debt-to-equity ratio of 0.02, signifying a healthy financial structure.
  • Institutional investors like iA Global Asset Management Inc. and Crestwood Advisors Group LLC have been increasing their holdings in the company, reflecting confidence in its future prospects.
  • The company's consistent performance and strategic investments have attracted significant institutional interest, with 90.77% of the company's stock owned by institutional investors and hedge funds.

Cons

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Vertex Pharmaceuticals' stock price experienced a decline during mid-day trading, reaching $411.85, which may indicate short-term volatility.
  • Chairman Jeffrey M. Leiden sold a significant number of shares, which could raise concerns about insider sentiment or future company performance.
  • While the company has shown stability, the PEG ratio of 2.31 suggests that the stock may be slightly overvalued compared to its earnings growth potential.
  • Recent insider activity, such as Ourania Tatsis selling shares, could be interpreted as a lack of confidence in the company's future performance.
  • Despite institutional interest, individual investors may face challenges in assessing the company's long-term growth prospects due to potential market fluctuations.

VRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 3 sell ratings, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRTX, but not buy additional shares or sell existing shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price target for 2024?

22 Wall Street analysts have issued twelve-month target prices for Vertex Pharmaceuticals' shares. Their VRTX share price targets range from $325.00 to $540.00. On average, they expect the company's share price to reach $417.27 in the next year. This suggests that the stock has a possible downside of 0.0%.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2024?

Vertex Pharmaceuticals' stock was trading at $406.89 on January 1st, 2024. Since then, VRTX shares have increased by 2.6% and is now trading at $417.32.
View the best growth stocks for 2024 here
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Monday, February, 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping analysts' consensus estimates of $3.85 by $0.35. The pharmaceutical company had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a trailing twelve-month return on equity of 21.91%. During the same quarter in the prior year, the business posted $3.33 earnings per share.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.6 billion-$10.8 billion, compared to the consensus revenue estimate of $10.6 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.65%), Vanguard Group Inc. (8.63%), Capital World Investors (8.46%), Price T Rowe Associates Inc. MD (2.28%), Wellington Management Group LLP (2.02%) and Jennison Associates LLC (1.53%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Carmen Bozic, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Jonathan Biller, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Ourania Tatsis, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
This page (NASDAQ:VRTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners